Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study on Anti-Amyloid-β Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Coverage of Evidence Development (The Anti-Aβ mAb CED Study)

NCT06058234 is registered in ClinicalTrials.gov with Centers for Medicare and Medicaid Services/ Coverage and Analysis Group as lead sponsor.

NCT NCT06058234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06058234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study on Anti-Amyloid-β Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Coverage of Evidence Development (The Anti-Aβ mAb CED Study)
Lead sponsor
Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Phase
Observational
Overall status
Recruiting
Start date
July 6, 2023
Completion date
June 30, 2029
Enrollment
8,680 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild alzheimer's disease, mild cognitive impairment (mci) due to alzheimer's disease